Amifostine
Brand names: ETHYOL
Therapeutic Indications
Amifostine is indicated for:
Reduction of side effects of cisplatin
Irrespective of gender only Adults (18 - 65 years old)
Amifostine is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 740-910 mg/m²
Reduction of xerostomia in patients undergoing radiotherapy
Irrespective of gender only Adults (18 - 65 years old)
Amifostine is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 200 mg/m2
Contraindications
Active ingredient Amifostine is contraindicated in the following cases:
Pregnancy
No gender/age discrimination
Amifostine has been shown to be embryotoxic in rabbits at doses of 50 mg/kg, approximately sixty percent of the recommended dose in humans on a body surface area basis. There are no adequate and well-controlled studies in pregnant women. Amifostine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
No gender/age discrimination
No information is available on the excretion of amifostine or its metabolites into human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants, it is recommended that breast feeding be discontinued if the mother is treated with amifostine.